.JPG)
.JPG)
Figure 1: Percentage of different platelet populations after ponatinib treatment
FIGURE 1
Figure 1: Percentage of different platelet populations after ponatinib treatment
Size in males |
|
|
|
|
PLT |
Controls |
Ponatinib 0.1 μM |
%Δ |
p value |
subpopulations |
|
|
|
|
PS+ |
112±16 |
148±15 |
+32% |
p≤0.05 |
CD62+ |
110±19 |
103±26 |
-6.4% |
|
PAC+ |
283±92.4 |
158±34 |
-44.2% |
|
Size in females |
|
|
|
|
PLT |
Controls |
Ponatinib 0.1 μM |
%Δ |
p value |
subpopulations |
|
|
|
|
PS+ |
120±13 |
124±11 |
+3.3% |
|
CD62+ |
117±12.7 |
108±8.4 |
-7.8% |
|
PAC+ |
265±53.7 |
145±52 |
-45.3% |
|
Granularity in males |
|
|
|
|
PLT |
Controls |
Ponatinib 0.1 μM |
%Δ |
p value |
subpopulations |
|
|
|
|
PS+ |
68±22 |
87.5±35 |
+28.7% |
p≤0.05 |
CD62+ |
65.5±30.5 |
61.5±27 |
-6.1% |
|
PAC+ |
253.3±25 |
344.5±33 |
+36% |
p≤0.05 |
Granularity in females |
|
|
|
|
PLT |
Controls |
Ponatinib 0.1 μM |
%Δ |
p value |
subpopulations |
|
|
|
|
PS+ |
94.8±16.7 |
103±27.8 |
+8.6% |
|
CD62+ |
78.25±15 |
76±20 |
-2.9% |
|
PAC+ |
278.5±22.5 |
350±41.3 |
+25.7% |
p≤0.05 |
Table 1: Morphology (size and granularity) of platelet subpopulations
*Platelet size was expressed as the media of median value of the FSC parameter. Platelet granularity was expressed as the media of median value of the SSC parameter
PLTs |
MALES |
p value |
FEMALES |
p value |
|
(n = 25) |
|
(n = 20) |
|
Necrotic |
+338% |
p ≤0.01 |
+320% |
p ≤ 0.01 |
Apoptotic |
+261% |
p ≤ 0.05 |
+168% |
p ≤ 0.05 |
CD62+ |
+48% |
p ≤ 0.05 |
+16% |
|
PAC+ |
+79% |
|
+226% |
|
Table 1: ?% of different platelet subpopulations after treatment with ponatinib 0.1 µM
Tables at a glance
Figures at a glance